AstraZeneca and CSPC partner on kidney-disease siRNA
Illustration (decorative, not data).Summary
The two companies will jointly discover and develop small-interfering-RNA drugs against two undisclosed kidney-disease targets, using CSPC's siRNA discovery platform and delivery tools that can carry drugs to organs beyond the liver, plus CSPC's AI molecular-design models and automated high-throughput screening. AstraZeneca may choose global or ex-China exclusive rights; CSPC retains China rights to one of the assets. siRNA has so far been largely limited to liver targets (GalNAc conjugation), and kidney delivery is widely seen as the industry's next hurdle. With only $30 million up front, this is an early discovery deal whose value rests mainly on later stages.
Deal terms, as disclosed
$30M upfront + $540M development milestones + $1.2B sales milestones.
Summary of public disclosures, not investment advice. Amounts are as announced; milestone payments are contingent and may never be paid.
Related same deal type
- Novartis takes global rights to Abogen's in vivo mRNA T-cell engager ABO2203Oct 2026
- Simcere Zaiming licenses CD79a×CD19×CD3 trispecific SIM0660 to RocheSep 2026
- Haisco immunology asset goes into ARCH-founded NewCo SentiveraAug 2026
- J&J locks up Sail Biomedicines' in vivo CAR-T with an equity stake and an acquisition optionJul 2026
Asset owners and investors: write to bd@inlightbio.com. Newsletter and report questions: contact@inlightbio.com.